Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03299686 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT03299686 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 118 participants.
The verdict
NCT03299686, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in development for T2-high(allergic/eosinophilic) asthma. The purpose of this study was to determine if CJM112, an anti-IL-17A antibody, displayed the clinical efficacy and safety profile to support further development in patients with inadequately controlled moderate to severe asthma with low IgE and low circulating eosinophil levels.
Interventions
- DRUG CJM112
- OTHER Placebo to CJM112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2019-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03299686
The ClinicalTrials.gov registry entry for NCT03299686 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CJM112 is the first listed.
NCT03299686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03299686 about?
NCT03299686 is a clinical study titled "Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma". An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in development for T2-high(allergic/eosinophilic) asthma. The purpose of this s...
What is the current status of trial NCT03299686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2017-11-06. Estimated completion is 2019-07-08.
What interventions are being tested in trial NCT03299686?
The interventions under investigation include: CJM112 (DRUG), Placebo to CJM112 (OTHER).
Who is sponsoring clinical trial NCT03299686?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.